USRE46285EExpiredUtility

Streptococcus suis polypeptides and polybnucleotides encoding same and their use in vaccinal and diagnostic applications

65
Assignee: VALORISATION-RECHERCHE LTD PARTNERSHIPPriority: Sep 2, 2005Filed: Sep 1, 2006Granted: Jan 24, 2017
Est. expirySep 2, 2025(expired)· nominal 20-yr term from priority
Inventors:Josee HarelMarcelo GottschalkYuanyi Li
G01N 2333/315C07K 14/315C07K 16/1275A61P 31/04A61K 39/092A61K 2039/505G01N 33/56944A61K 2039/552A61P 31/00A61K 2039/53A61K 39/09A61K 39/00
65
PatentIndex Score
1
Cited by
67
References
34
Claims

Abstract

The present invention relates to the field of Streptococcus. More specifically, the present invention relates to the identification of polypeptides and polynucleotide sequences encoding the same which are involved in the pathogenic mechanism of S. suis. The present invention also relates to the use of such polypeptides in compositions and methods for the prevention, the treatment and diagnosis of S. suis-associated diseases and infections caused by S. suis.

Claims

exact text as granted — not AI-modified
The invention claimed is: 
     
       1. An isolated polypeptide comprising an amino acid sequence having at least 75% identity to the amino acid sequence set forth in SEQ ID NO: 1 or in SEQ ID NO: 4. 
     
     
       2. The isolated polypeptide of  claim 1 , comprising at least one repetitive amino acid sequence consisting of the amino acid sequence Xaa 1  Ser Xaa 3  Xaa 4  Xaa 5  Met Xaa 7  Xaa 8  Xaa 9  Xaa 10  Xaa 11  Xaa 12  Xaa 13  Xaa 14  Xaa 15  Xaa 16  Pro Xaa 18  Xaa 19  Gln Met Xaa 22  Asn Lys Glu Xaa 26  Xaa 27  Xaa 28  Xaa 29  Xaa 30  SEQ ID NO 9) wherein
 Xaa 1  is Val, Thr or Ile;   Xaa 3  is Lys or Glu;   Xaa 4  is Lys or Glu;   Xaa 5  is Ala or Gln;   Xaa 7  is Thr or Pro;   Xaa 8  is Gly, Ser or Val;   Xaa 9  is Lys, VaI, Ile or Asn;   Xaa 10  is Glu or Val;   Xaa 11  is Lys or Asn;   Xaa 12  is Gly, Glu or Asp;   Xaa 13  is Asn or Met;   Xaa 14  is Ile, Ala or Val;   Xaa 15  is Glu or Val;   Xaa 16  is Pro or Thr;   Xaa 18  is Glu or Gln;   Xaa 19  is Lys or Glu;   Xaa 22  is Thr or Ala;   Xaa 26  is Lys or Asn;   Xaa 27  is Asp or Glu;   Xaa 28  is Asn or Lys;   Xaa 29  is Ile or Val and   Xaa 30  is Glu or Val.   
     
     
       3. The isolated polypeptide of  claim 1 , comprising the amino acid sequence as set forth in SEQ ID NO 10. 
     
     
       4. The isolated polypeptide of  claim 1 , comprising an amino acid having at least 85% identity to the amino acid sequence set forth in SEQ ID NO 1 or in SEQ ID NO 4. 
     
     
       5. The isolated polypeptide of  claim 1 , comprising an amino acid sequence having at least 95% identity to the amino acid sequence set forth in SEQ ID NO 1. 
     
     
       6. The isolated polypeptide of  claim 1 , comprising an amino acid sequence having at least 95% identity to the amino acid sequence set forth in SEQ ID NO 4. 
     
     
       7. The isolated polypeptide of  claim 1 , wherein it elicits a protective response to a Streptococcus suis strain challenge when administered to an animal. 
     
     
       8. The isolated polypeptide of  claim 3 , comprising at least one repetitive amino acid sequence consisting of the amino acid sequence Xaa 1  Ser Xaa 3  Xaa 4  Xaa 5  Met Xaa 7  Xaa 8  Xaa 9  Xaa 10  Xaa 11  Xaa 12  Xaa 13  Xaa 14  Xaa 15  Xaa 16  Pro Xaa 18  Xaa 19  Gln Met Xaa 22  Asn Lys Glu Xaa 26  Xaa 27  Xaa 28  Xaa 29  Xaa 30  SEQ ID NO 9) wherein
 Xaa 1  is Val, Thr or Ile;   Xaa 3  is Lys or GIu;   Xaa 4  is Lys or GIu;   Xaa 5  is Ala or Gln;   Xaa 7  is Thr or Pro;   Xaa 8  is Gly, Ser or Val;   Xaa 9  is Lys, VaI, Ile or Asn;   Xaa 10  is Glu or Val;   Xaa 11  is Lys or Asn;   Xaa 12  is Gly, Glu or Asp;   Xaa 13  is Asn or Met;   Xaa 14  is Ile, Ala or Val;   Xaa 15  is Glu or Val;   Xaa 16  is Pro or Thr;   Xaa 18  is Glu or Gln;   Xaa 19  is Lys or Glu;   Xaa 22  is Thr or Ala;   Xaa 26  is Lys or Asn;   Xaa 27  is Asp or Glu;   Xaa 28  is Asn or Lys;   Xaa 29  is Ile or Val and   Xaa 30  is Glu or Val.   
     
     
       9. The isolated polypeptide of  claim 4 , comprising at least one repetitive amino acid sequence consisting of the amino acid sequence Xaa 1  Ser Xaa 3  Xaa 4  Xaa 5  Met Xaa 7  Xaa 8  Xaa 9  Xaa 10  Xaa 11  Xaa 12  Xaa 13  Xaa 14  Xaa 15  Xaa 16  Pro Xaa 18  Xaa 19  Gln Met Xaa 22  Asn Lys Glu Xaa 26  Xaa 27  Xaa 28  Xaa 29  Xaa 30  (SEQ ID NO 9) wherein
 Xaa 1  is Val, Thr or Ile;   Xaa 3  is Lys or GIu;   Xaa 4  is Lys or GIu;   Xaa 5  is Ala or Gln;   Xaa 7  is Thr or Pro;   Xaa 8  is Gly, Ser or Val;   Xaa 9  is Lys, VaI, Ile or Asn;   Xaa 10  is GIu or Val;   Xaa 11  is Lys or Asn;   Xaa 12  is Gly, Glu or Asp;   Xaa 13  is Asn or Met;   Xaa 14  is Ile, Ala or Val;   Xaa 15  is Glu or Val;   Xaa 16  is Pro or Thr;   Xaa 18  is Glu or Gln;   Xaa 19  is Lys or Glu;   Xaa 22  is Thr or Ala;   Xaa 26  is Lys or Asn;   Xaa 27  is Asp or Glu;   Xaa 28  is Asn or Lys;   Xaa 29  is Ile or Val and   Xaa 30  is Glu or Val.   
     
     
       10. The isolated polypeptide of  claim 5 , comprising at least one repetitive amino acid sequence consisting of the amino acid sequence Xaa 1  Ser Xaa 3  Xaa 4  Xaa 5  Met Xaa 7  Xaa 8  Xaa 9  Xaa 10  Xaa 11  Xaa 12  Xaa 13  Xaa 14  Xaa 15  Xaa 16  Pro Xaa 18  Xaa 19  Gln Met Xaa 22  Asn Lys Glu Xaa 26  Xaa 27  Xaa 28  Xaa 29  Xaa 30  (SEQ ID NO 9) wherein
 Xaa 1  is Val, Thr or Ile;   Xaa 3  is Lys or GIu;   Xaa 4  is Lys or GIu;   Xaa 5  is Ala or Gln;   Xaa 7  is Thr or Pro;   Xaa 8  is Gly, Ser or Val;   Xaa 9  is Lys, VaI, Ile or Asn;   Xaa 10  is Glu or Val;   Xaa 11  is Lys or Asn;   Xaa 12  is Gly, Glu or Asp;   Xaa 13  is Asn or Met;   Xaa 14  is Ile, Ala or Val;   Xaa 15  is Glu or Val;   Xaa 16  is Pro or Thr;   Xaa 18  is Glu or Gln;   Xaa 19  is Lys or Glu;   Xaa 22  is Thr or Ala;   Xaa 26  is Lys or Asn;   Xaa 27  is Asp or Glu;   Xaa 28  is Asn or Lys;   Xaa 29  is Ile or Val and   Xaa 30  is Glu or Val.   
     
     
       11. The isolated polypeptide of  claim 6 , comprising at least one repetitive amino acid sequence consisting of the amino acid sequence Xaa 1  Ser Xaa 3  Xaa 4  Xaa 5  Mel Xaa 7  Xaa 8  Xaa 9  Xaa 10  Xaa 11  Xaa 12  Xaa 13  Xaa 14  Xaa 15  Xaa 16  Pro Xaa 18  Xaa 19  Gln Met Xaa 22  Asn Lys Glu Xaa 26  Xaa 27  Xaa 28  Xaa 29  Xaa 30  (SEQ ID NO 9) wherein
 Xaa 1  is Val, Thr or Ile;   Xaa 3  is Lys or GIu;   Xaa 4  is Lys or GIu;   Xaa 5  is Ala or Gln;   Xaa 7  is Thr or Pro;   Xaa 8  is Gly, Ser or Val;   Xaa 9  is Lys, VaI, Ile or Asn;   Xaa 10  is GIu or Val;   Xaa 11  is Lys or Asn;   Xaa 12  is Gly, Glu or Asp;   Xaa 13  is Asn or Met;   Xaa 14  is Ile, Ala or Val;   Xaa 15  is Glu or Val;   Xaa 16  is Pro or Thr;   Xaa 18  is Glu or Gln;   Xaa 19  is Lys or Glu;   Xaa 22  is Thr or Ala;   Xaa 26  is Lys or Asn;   Xaa 27  is Asp or Glu;   Xaa 28  is Asn or Lys;   Xaa 29  is Ile or Val and   Xaa 30  is Glu or Val.   
     
     
       12. The isolated polypeptide of  claim 1 , comprising an amino acid sequence having 100% identity to the amino acid sequence set forth in SEQ ID NO 1. 
     
     
       13. The isolated polypeptide of  claim 1 , comprising an amino acid sequence having 100% identity to the amino acid sequence set forth in SEQ ID NO 4. 
     
     
       14. An isolated polypeptide, comprising an amino acid sequence having at least 95% identity to the amino acid sequence set forth in SEQ ID NO 2. 
     
     
       15. The isolated polypeptide of  claim 14 , comprising an amino acid sequence having 100% identity to the amino acid sequence set forth in SEQ ID NO 2. 
     
     
       16. An isolated polypeptide, comprising an amino acid sequence having at least 95% identity to the amino acid sequence set forth in SEQ ID NO 3. 
     
     
       17. The isolated polypeptide of  claim 16 , comprising an amino acid sequence having 100% identity to the amino acid sequence set forth in SEQ ID NO 3. 
     
     
       18. A composition comprising an acceptable carrier and at least one of the following elements:
 a polypeptide as defined in any one of  claims 1 ,  2 ,  3 ,  4 ,  5 ,  6 ,  7 , and  8  to  17 .   
     
     
       19. A composition for eliciting an immune response to Streptococcus or treating Streptococcus suis-associated diseases or infection caused by S. suis, comprising an acceptable carrier and at least one of the following elements:
 a polypeptide as defined in any one of  claims 1 ,  2 ,  3 ,  4 ,  5 ,  6 ,  7 , and  8  to  17 .   
     
     
       20. The composition of  claim 19 , further comprising an adjuvant. 
     
     
       21. A method of screening for a polypeptide having immunogenic potential for preventing a Streptococcus suis-associated disease, comprising:
 (a) administering to an animal, a test polypeptide comprising at least 15 contiguous amino acids of the amino acid sequence of SEQ ID NO: 4; and   (b) processing a biological sample from said animal to detect the presence or absence in said sample of an antibody having binding specificity to the polypeptide, wherein the presence of said antibody is indicative of the polypeptide having immunogenic potential for preventing the Streptococcus suis-associated disease.   
     
     
       22. The method of claim 21, wherein the test polypeptide comprises at least 25 contiguous amino acids of the amino acid sequence of SEQ ID NO: 4. 
     
     
       23. The method of claim 21, wherein the test polypeptide comprises at least 35 contiguous amino acids of the amino acid sequence of SEQ ID NO: 4. 
     
     
       24. The method of claim 21, wherein the test polypeptide comprises the amino acid sequence of SEQ ID NO: 9. 
     
     
       25. The method of claim 24, wherein the amino acid sequence of SEQ ID NO: 9 is a first repetitive amino acid sequence of a plurality of said repetitive amino acid sequence. 
     
     
       26. The method of claim 21, wherein said polypeptide is a recombinant polypeptide. 
     
     
       27. The method of claim 21, wherein said animal is a pig. 
     
     
       28. A method for preventing a Streptococcus suis-associated disease in an animal, comprising administering to the animal a polypeptide comprising at least 15 contiguous amino acids of the amino acid sequence of SEQ ID NO: 4. 
     
     
       29. The method of claim 28, said animal being a pig. 
     
     
       30. A microbial culture, comprising cells having a recombinant DNA molecule encoding a polypeptide comprising an amino acid sequence having at least 95% identity to the amino acid sequence set forth in SEQ ID NO: 4. 
     
     
       31. A method for producing a polypeptide comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4, comprising cultivating a microbial culture comprising cells having a recombinant DNA molecule encoding said polypeptide under conditions conducive for production of said polypeptide, and recovering said polypeptide. 
     
     
       32. A method for preventing a Streptococcus suis-associated disease in an animal, comprising administering to the animal a polypeptide comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4. 
     
     
       33. The method of claim 28, wherein the polypeptide comprises at least 25 contiguous amino acids of the amino acid sequence of SEQ ID NO: 4. 
     
     
       34. The method of claim 28, wherein the polypeptide comprises at least 35 contiguous amino acids of the amino acid sequence of in SEQ ID NO: 4.

Join the waitlist — get patent alerts

Track USRE46285E — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.